Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.49 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL281503 | 0.89 | SCN9A (0.49) | MCHR1ALDH1A1TAS1R3TAS1R1SCN9A | |
| SCHEMBL281032 | 0.87 | SCN9A (0.54) | MCHR1ALDH1A1SCN9ASCN7ASCN5A | |
| SCHEMBL281197 | 0.86 | SCN9A (0.53) | MCHR1ALDH1A1SCN9ASCN7ASCN5A | |
| SCHEMBL281271 | 0.86 | SCN9A (0.53) | MCHR1ALDH1A1SCN9ASCN7ASCN5A | |
| SCHEMBL280704 | 0.86 | SCN9A (0.53) | MCHR1ALDH1A1TAS1R3TAS1R1SCN9A | |
| SCHEMBL281351 | 0.85 | SCN9A (0.52) | ALDH1A1SCN9ASCN7ASCN5ASCN2A | |
| SCHEMBL281378 | 0.83 | SCN9A (0.56) | MCHR1ALDH1A1SCN9ASCN7ASCN5A | |
| SCHEMBL280860 | 0.83 | SCN9A (0.59) | ALDH1A1SCN9ASCN7ASCN5ASCN2A | |
| SCHEMBL280965 | 0.82 | SLC6A12 (0.62) | MCHR1ALDH1A1SCN9ASCN7ASCN5A | |
| SCHEMBL281529 | 0.82 | SCN9A (0.56) | MCHR1ALDH1A1SCN9ASCN7ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888595-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-01 | — | — | EP | claimed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | claimed |
| EP-3241834-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2017-11-08 | — | — | EP | disclosed |
| EP-2752417-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2014-07-09 | — | — | EP | disclosed |
| US-8466188-B2 | Use of spiro-oxindole compounds as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-06-18 | — | — | US | disclosed |
| EP-2428515-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
| EP-2073806-B1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-15 | — | — | EP | disclosed |
| EP-1888595-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-01 | — | — | EP | disclosed |
| US-20110172282-A9 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-07-14 | — | — | US | disclosed |
| US-20100173967-A1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172282-A9 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | KLK3, REN, AVPR1B | MCHR1 849/4885ALDH1A1 1202/4885TAS1R3 2252/4885 |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | OPRK1, OPRD1, SCN3A | MCHR1 1846/4885ALDH1A1 838/4885TAS1R3 1570/4885 |
| US-20100173967-A1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | KLK3, REN, AVPR1B | MCHR1 849/4885ALDH1A1 1202/4885TAS1R3 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.